Literature DB >> 25561419

Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications.

James H Flory1, Sean Hennessy2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25561419     DOI： 10.1001/jamainternmed.2014.6936

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  16 in total

1.  Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.

Authors:  Zachary A Marcum; Christopher W Forsberg; Kathryn P Moore; Ian H de Boer; Nicholas L Smith; Edward J Boyko; James S Floyd
Journal:  J Gen Intern Med       Date:  2017-11-27       Impact factor: 5.128

2.  The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD.

Authors:  Jung-Im Shin; Yingying Sang; Alex R Chang; Stephan C Dunning; Josef Coresh; Lesley A Inker; Elizabeth Selvin; Shoshana H Ballew; Morgan E Grams
Journal:  J Am Soc Nephrol       Date:  2020-07-13       Impact factor: 10.121

3.  A retrospective cohort analysis of hypoglycaemic and cardiovascular agent use in young adults in the Irish primary care setting.

Authors:  R T Grimes; K Bennett; H Hoey; L Tilson; M C Henman
Journal:  Ir J Med Sci       Date:  2016-08-17       Impact factor: 1.568

Review 4.  Lactate Levels with Chronic Metformin Use: A Narrative Review.

Authors:  Weiyi Huang; Ronald L Castelino; Gregory M Peterson
Journal:  Clin Drug Investig       Date:  2017-11       Impact factor: 2.859

Review 5.  Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.

Authors:  Jeryl Villadolid; Jennifer L Ersek; Mei Ka Fong; Lindsey Sirianno; Ellen S Story
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 6.  Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.

Authors:  L I Igel; A Sinha; K H Saunders; C M Apovian; D Vojta; L J Aronne
Journal:  Curr Atheroscler Rep       Date:  2016-04       Impact factor: 5.113

7.  Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke.

Authors:  James S Floyd; Kerri L Wiggins; Mark Christiansen; Sascha Dublin; William T Longstreth; Nicholas L Smith; Barbara McKnight; Susan R Heckbert; Noel S Weiss; Bruce M Psaty
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-08       Impact factor: 2.890

8.  Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.

Authors:  Benjamin Lazarus; Aozhou Wu; Jung-Im Shin; Yingying Sang; G Caleb Alexander; Alex Secora; Lesley A Inker; Josef Coresh; Alex R Chang; Morgan E Grams
Journal:  JAMA Intern Med       Date:  2018-07-01       Impact factor: 21.873

Review 9.  Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.

Authors:  Matthew J Crowley; Clarissa J Diamantidis; Jennifer R McDuffie; C Blake Cameron; John W Stanifer; Clare K Mock; Xianwei Wang; Shuang Tang; Avishek Nagi; Andrzej S Kosinski; John W Williams
Journal:  Ann Intern Med       Date:  2017-01-03       Impact factor: 25.391

10.  Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.

Authors:  M Elle Saine; Dena M Carbonari; Craig W Newcomb; Melissa S Nezamzadeh; Kevin Haynes; Jason A Roy; Serena Cardillo; Sean Hennessy; Crystal N Holick; Daina B Esposito; Arlene M Gallagher; Harshvinder Bhullar; Brian L Strom; Vincent Lo Re
Journal:  BMC Pharmacol Toxicol       Date:  2015-04-02       Impact factor: 2.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.